RILMAKALIM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H23NO5S
Molecular Weight	401.476
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)OC2=C(C=C(C=C2)S(=O)(=O)C3=CC=CC=C3)[C@H]([C@@H]1O)N4CCCC4=O

InChI

InChIKey=LKAQWOWWTKFLNX-UXHICEINSA-N

InChI=1S/C21H23NO5S/c1-21(2)20(24)19(22-12-6-9-18(22)23)16-13-15(10-11-17(16)27-21)28(25,26)14-7-4-3-5-8-14/h3-5,7-8,10-11,13,19-20,24H,6,9,12H2,1-2H3/t19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H23NO5S
Molecular Weight	401.476
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://jpet.aspetjournals.org/content/268/2/818.short | https://adisinsight.springer.com/drugs/800001252 | https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.1993.tb05701.x | https://www.ncbi.nlm.nih.gov/pubmed/1601049

Rilmakalim (HOE-234) is a potassium channel activator and dilator of bronchial and vascular smooth muscles. An animal study showed that rilmakalim is effective against contractile response induced by asthma mediators in guinea pig airways and has the potential to act against asthma attacks, because it acts on acute bronchospasm. The activation of ATP-sensitive potassium channels is likely to be involved in the smooth muscle relaxation produced by rilmakalim in human airways. This drug has been investigated for use in asthma and coronary disorders, but development has been discontinued.

Originator

Approval Year

Patents

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:39:43 GMT 2025` Edited by `admin` on `Wed Apr 02 09:39:43 GMT 2025`
Record UNII	47Y56T6LEI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RILMAKALIM

Official Name

English

rilmakalim [INN]

Preferred Name

English

Classification Tree Code System Code

NCI_THESAURUS

C270